Research ArticleArticle
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort
Jenny Shu, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Diane Tin, Edward C. Keystone and Janet E. Pope for CATCH Investigators
The Journal of Rheumatology September 2015, jrheum.150260; DOI: https://doi.org/10.3899/jrheum.150260
Jenny Shu
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Vivian P. Bykerk
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Gilles Boire
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Boulos Haraoui
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Carol Hitchon
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
J. Carter Thorne
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Diane Tin
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Edward C. Keystone
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
Janet E. Pope
From the Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario; Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto; Rheumatology, St. Joseph’s Health Care, Toronto; Southlake Regional Health Centre, Newmarket, Ontario, Canada; Rheumatology Division, Universite de Sherbrooke, Sherbrooke; Rheumatic Disease Unit, Institut de Rhumatologie, Montreal, Quebec; Arthritis Centre, University of Manitoba, Winnipeg, Manitoba, Canada; Rheumatology, Hospital for Special Surgery, Cornell University, New York, New York, USA. The CATCH study was designed and implemented by the investigators and financially supported initially by Amgen Canada Inc. and Pfizer Canada Inc. by an unrestricted research grant since inception of CATCH. As of 2011, further support was provided by Hoffmann-La Roche Ltd., United Chemicals of Belgium Canada Inc., Bristol-Myers Squibb Canada Co., AbbVie Inc., and Janssen Biotech Inc. (a wholly owned subsidiary of Johnson & Johnson Inc.). Some funds for analysis were from the Program of Experimental Medicine, Department of Medicine, University of Western Ontario, London, Ontario, Canada. J. Shu, FRCPC, Department of Medicine, Schulich School of Medicine and Dentistry, Western University; V.P. Bykerk, MD, Rheumatology, Mount Sinai Hospital, University of Toronto, and Rheumatology, Hospital for Special Surgery, Cornell University; G. Boire, MD, Rheumatology Division, Universite de Sherbrooke; B. Haraoui, MD, Rheumatic Disease Unit, Institut de Rhumatologie; C. Hitchon, MD, Arthritis Centre, University of Manitoba; J.C. Thorne, MD, Southlake Regional Health Centre; D. Tin, MD, Southlake Regional Health Centre; E.C. Keystone, MD, Rheumatology, Mount Sinai Hospital, University of Toronto; Janet E. Pope, MD, Department of Medicine, Schulich School of Medicine and Dentistry, Western University, and Rheumatology, St. Joseph’s Health Care. Address correspondence to Dr. J. Pope, 268 Grosvenor St., London, Ontario N6A 4V2, Canada. E-mail: janet.pope@sjhc.london.on.ca. Accepted for publication July 2, 2015.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort
Jenny Shu, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Diane Tin, Edward C. Keystone, Janet E. Pope
The Journal of Rheumatology Sep 2015, jrheum.150260; DOI: 10.3899/jrheum.150260
Missing Anticitrullinated Protein Antibody Does Not Affect Short-term Outcomes in Early Inflammatory Arthritis: From the Canadian Early Arthritis Cohort
Jenny Shu, Vivian P. Bykerk, Gilles Boire, Boulos Haraoui, Carol Hitchon, J. Carter Thorne, Diane Tin, Edward C. Keystone, Janet E. Pope
The Journal of Rheumatology Sep 2015, jrheum.150260; DOI: 10.3899/jrheum.150260